KO-7246

October 7, 2026: Caspian Therapeutics and Kura Oncology (NASDAQ: KURA) announced an investor webcast for October 13, 2026 at 4:30 p.m. ET to discuss the formation of Caspian and review KO-7246 data presented in an oral session at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting.

KO-7246 is described as Caspian’s lead compound, a next-generation, highly selective oral menin inhibitor for metabolic applications. The program is currently in IND-enabling development, and Caspian plans a Phase 1 trial to evaluate whether KO-7246 can restore functional beta-cell capacity and endogenous insulin production in patients with diabetes.

The release also states Caspian plans to advance a second development candidate for additional cardiometabolic indications. No trial results or detailed EASD data are included in the content.